Trialbee announces partnership with Massive Bio to share mission of reaching more patients than ever
The company recently announced its Omnichannel Network partnership with Massive Bio, a global leader in AI-enabled patient journey mapping platform, to help better connect cancer patients and their oncologists/haematologists to clinical trials.
Adamski, senior director of omnichannel solutions, says that because of the difficulty in recruiting for cancer trials the companies are ‘bringing their best and biggest pitchforks’.
Trialbee helps patients get enrolled in trials, finds new referrals, and manages them through to trial sites.
“With our shared mission, Massive Bio helps us reach more patients than ever. We realize one recruitment channel isn’t enough on its own. That’s why we have built our Omnichannel Network with partnerships like this so more patients can discover the possibilities of clinical research as a care option,” she added.
According to the US Commission on Cancer, only 6.3% of patients participate in clinical research for cancer treatments, which makes it imperative to raise awareness of research opportunities as a care option.
Trialbee and Massive Bio say they understand that patients have so much going on in their lives and with their care, that clinical research isn’t typically top of mind for them, their families, or even their oncologists – while others may lack the time or knowledge of where to look, or the questions to ask.
The companies are committed to working together and acting now as they say many of these trials potentially represent the newest most innovative methods to save lives and could improve the outlook for generations to come.
“Our mission is to raise awareness with our global patient and provider contact centres, physician-to-physician referrals, and mega channel partnerships with a specific focus on oncology and haematology studies,” said Selin Kurnaz, CEO of Massive Bio.
“We aggregate all of these direct and indirect pathways while providing services for medical records collection, molecular diagnostics testing results collection (aka NGS testing), master pre-screening, and last-mile support including referral, logistics, and financial, to make it easier for cancer patients to participate.
“This partnership with Trialbee brings another channel of identification and outreach with hyper-targeted digital recruitment so we can reach more patients together – including those at community-based practices, which was the founding reason of Massive Bio, so we can improve health equity and access for all.”
The companies agree they share similar approaches to recruitment for cancer trials with an emphasis on patient-centred research coupled with total transparency to ensure sites have the information they need to follow-up with interested study candidates.
“Complex patient recruitment challenges require a thoughtful strategy and, frankly, a new approach,” said Matt Walz, CEO of Trialbee.
“We have built our Omnichannel Network to expand the reach of our own data-driving recruitment methods without sacrificing our core principles of being highly targeted in our outreach. Massive Bio is a perfect example of a valuable partnership that will open new pathways for patients while still remaining hyper-focused on the ideal participant personae for each clinical trial. We are impressed by the team at Massive Bio, and we are proud to collaborate with them to raise awareness of clinical trial opportunities for more, and more diverse, patients and families worldwide.”
Visit Massive Bio at the Trialbee exhibit booth (#1209) at the SCOPE Summit on Feb 11-14, in Orlando, FL to the collaboration and how it improves awareness and recruitment for oncology and hematology clinical trials.
Interested participants will be tracked and managed within the Trialbee Honey Platform, which centralizes and standardizes recruitment and enrolment data from all sources to provide unprecedented transparency into the process while reducing the burden on sites.
